As a fully human monoclonal antibody targeting IGF-1R that inhibits IGF-1R-mediated signaling pathways by binding to the IGF-1R complex, teprotumumab alleviates inflammation and improves symptoms, such as proptosis and diplopia. The gene discussed is IGF1R; the disease is Diplopia.